Gilead Misses Analysts’ Estimates on Sales of HIV Drugs

Gilead Sciences Inc., the world’s biggest maker of AIDS medicines, reported first-quarter profit that missed analysts’ estimates on declining sales of its HIV drugs.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.